Vertex Pharmaceuticals

Our 2021 portfolio performed decently - THE EDGE SINGAPORE

Global review

Our 2021 portfolio performed decently

The Edge Singapore’s 2021 global portfolio returned 13.1% for the period of Feb 18, 2021, to Jan 26, 2022.
The Edge has the lead - THE EDGE SINGAPORE

Investing ideas

Mid-year review: How The Edge Singapore's top 10 global stock picks fared

At the mid-year mark, our portfolio of 10 global stock picks for this year is up by a quarter.
The STI beats us but we beat the rest - THE EDGE SINGAPORE

Investing ideas

The STI beats us but we beat the rest

The top performer was Ted Baker with a whopping 74.9% gain while the worst performer was CrowdStrike Holdings with a 12.8% loss.
Vertex Pharmaceuticals: Dominant moat, strong pipeline - THE EDGE SINGAPORE

Stocks To Watch

Vertex Pharmaceuticals: Dominant moat, strong pipeline

Specialist in cystic fibrosis medication plans to raise growth potential with expanding portfolio.
×